EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES

Ebrahimnegad, Hami Reza; Boojar, Mahdi Mashhadi Akbar; Cheraghali, Abdol Majid; Shankayi, Zeinab; Mohammadzadeh, Tahereh; Mirasheh, Mohammad Hassan; Poorhaji, Mohammad Mahdi; Eidnezhad, Mohammad Hosein; Shahriari, Maryam; Asadi, Mohammad Mahdi; Amanpoor, Hassan; Nikpouraghdam, Mohammad; Bahrami, Farideh

doi:10.21608/bfsa.2021.174134

EVALUATION OF PHARMACOTHERAPY PROTOCOLS FOR COVID 19 PATIENTS IN BAQIYATALLAH HOSPITAL AND THEIR OUTCOMES

Document Type : Original Article

Authors

¹ Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran & Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

³ Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran & Department of Physiology and Medical Physics, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁴ Health and Nutrition Research Center, Baghiyatallah Medical Sciences University, Tehran, Iran

⁵ Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

10.21608/bfsa.2021.174134

Abstract

Purpose: The propagation of the new coronavirus, COVID 19, is still a major priority for many countries around the world. Because of the lack of effective certain antiviral therapy for COVID 19. Special medicinal protocols are needed in medical centers to reduce the mortality rate. Methods: Due to constant change of national pharmacotherapy protocols for COVID-19 patients, this study compares the outcomes of three specific pharmacotherapy regimens (Table 1) and the combination of all 3 regimens for management of 614 COVID-19 patients hospitalized in Baqiyatallah hospital in Tehran, this hospital became a referral centers for receiving COVID 19 patients in Iran. Results: The more reliable result of treatments belongs to regimen 3 which indicated 98.26% recovered patients and 1.15% mortality rate and the lowest period of hospitalization with 4.4±0.21 days’ duration. Conclusion: It seems that regimen 3 (with a special combination of antiviral and Azithromycin ant anti-inflammatory drugs) had the best result in improving patients with COVID 19 and this result has not conflict with the comorbidity status of patients.